{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-009784","form_type":"8-K","ticker":"WVE","cik":"0001631574","company_name":"Wave Life Sciences Ltd.","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.691349+00:00","generated_at":"2026-05-16T10:53:02.327936+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Wave Life Sciences reports preliminary $602M cash; outlines 2026 pipeline milestones","bullets":["Preliminary unaudited cash $602M as of Dec 31, 2025; runway into 3Q 2028.","WVE-007 Phase 2a multidose for obesity to start 1H 2026; 400mg 3-mo & 240mg 6-mo data due Q1 2026.","WVE-006 400mg multidose data from RestorAATion-2 expected Q1 2026; CTA for WVE-008 in 2026.","NDA filing for WVE-N531 (DMD exon 53 skipping) on track for 2026.","Plan to submit IND for WVE-003 (Huntington's) with prospective strategic partner."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-009784","json":"https://secwatch.observer/filing/0001193125-26-009784.json","markdown":"https://secwatch.observer/filing/0001193125-26-009784.md","text":"https://secwatch.observer/filing/0001193125-26-009784.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1631574/000119312526009784/0001193125-26-009784-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1631574/000119312526009784/d45710d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:53:02.327936+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}